CAR NK-cells project
An SWG Grant-supported project initiated by EHA's SWG on Immune Therapies for Hematologic Disorders.
Full project title
‘CAR NK-cells for tumor-associated macrophage immunomodulation – a new era of immunotherapy.’
Project lead
Dr Ciprian Tomuleasa
M.D.
MEDFUTURE Research Center for Advanced Medicine, UMF ‘Iuliu Hațieganu,’ Cluj-Napoca
Romania
Project background and aims
The project aims to design a CAR NK-based therapy and test it in the preclinical setting.
For many years, chemotherapy and radiation therapy were the three main therapeutic pillars for hematological malignancies.
Today, a fourth ground-breaking field of immunotherapies is quickly emerging. Known as adoptive cellular therapies, they offer long-term therapy possibilities—even for stages of disease progression that were previously incurable.
Adoptive cellular therapies such as CAR-T cells have already shown remarkable successes, mostly in treatment of acute lymphoblastic leukemia (ALL) and B-cell lymphomas.
This project aims to:
- Design a CAR NK-based therapy for multiple myeloma and B-cell lymphomas
- Test it in the preclinical setting
Back